Hims & Hers Health Inc.

21/11/2024 | Press release | Distributed by Public on 21/11/2024 20:29

Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On November 15, 2024, the board of directors (the "Board") of Hims & Hers Health, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Deb Autor, 57, to fill the newly created vacancy, effective immediately. Ms. Autor will serve until the Company's 2025 annual meeting of stockholders and until her successor is elected and qualified, or sooner in the event of her death, resignation or removal. The Board has determined that Ms. Autor meets the requirements for independence under the applicable listing standards of the New York Stock Exchange and the Securities Exchange Act of 1934, as amended.
Ms. Autor will be entitled to receive compensation as outlined in the "Director Compensation" section in the Company's proxy statement filed with the Securities and Exchange Commission on April 26, 2024. In addition, in connection with Ms. Autor's appointment as a member of the Company's Board, she has entered into a consulting agreement (the "Consulting Agreement") pursuant to which she will provide consulting services to the Company for a one-year period and will receive a consulting fee of $100,000. Ms. Autor or the Company may terminate this Consulting Agreement (i) without cause, upon 30 calendar days' written notice to the other party, or (ii) upon material breach by the other party, with 15 calendar days' notice, unless the breach is cured within such period, or immediately if such material breach is not curable. The foregoing description of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, which will be filed as an exhibit to the Company's Form 10-K for the year ended December 31, 2024. Ms. Autor has also entered into the Company's standard form of indemnification agreement.
There are no arrangements or understandings between Ms. Autor and any other persons pursuant to which she was elected as a member of the Company's Board. There are no family relationships between Ms. Autor and any director, executive officer, or any person nominated or chosen by the Company to become a director or executive officer. Ms. Autor is not a party to any current or proposed transaction with the Company for which disclosure is required under Item 404(a) of Regulation S-K.
Additionally, Ms. Autor has been appointed to the Risk Committee of the Board, effective as of November 15, 2024. Other directors also appointed to the Risk Committee as of this date include Christopher Payne, Anja Manuel, Kåre Schultz, and David Wells.